RT Journal Article
SR Electronic
T1 Neuroinflammation distinguishes HLA haplotypes in progressive supranuclear palsy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2025.07.21.25331869
DO 10.1101/2025.07.21.25331869
A1 Forrest, Shelley L.
A1 Zaheer, Sarah S.
A1 Kim, Ain
A1 Tanaka, Hidetomo
A1 Chasiotis, Helen
A1 Li, Jun
A1 Fox, Susan H.
A1 Wang, Jinguo
A1 Tartaglia, M. Carmela
A1 Lang, Anthony E.
A1 Kovacs, Gabor G.
YR 2025
UL http://medrxiv.org/content/early/2025/07/21/2025.07.21.25331869.abstract
AB Objectives Progressive supranuclear palsy (PSP) is a neurodegenerative 4R tauopathy clinically presenting with atypical parkinsonism or cognitive behavioral changes and a relatively uniform neuropathology. We recently identified rare HLA haplotypes in PSP and now examine whether HLA haplotypes are associated with different cytopathological and clinical phenotypes.Methods Retrospective collection of clinical data and mapping of T and B cells, microglia, and phosphorylated-tau (p-Tau) cytopathologies in 32 PSP cases. Machine learning was used to analyze whether pathological variables and their ratios, or the sequence of clinical symptoms cluster or predict HLA haplotypes.Results Four groups were defined based on HLA haplotypes: i) 12 cases with the haplotype associated with narcolepsy (DRB1*15:01-DQB1*06:02); ii) 11 cases with other DQ5-DQ6 haplotypes; iii) 8 cases with various haplotypes frequent in the general population; and iv) one case with the haplotype frequent in IgLON5-disease (DRB1*10:01-DQB1*05:01). Neuropathology revealed regional differences in the severity of microglia load, density of cytotoxic T cells, and p-Tau cytopathologies between groups. HLA haplotypes were most distinguishable using machine learned features of inflammatory markers and ratios of neuropathological variables (clustering accuracy: 86.96% and 91.30%, respectively). The sequence of clinical symptoms and the ratios of neuropathological variables were the strongest predictors of HLA haplotypes (prediction accuracy=80.00% and 71.43%, respectively).Interpretation PSP pathology might be associated with various etiological-pathogenic events including targetable autoimmune mechanisms. The HLA-haplotype dependent diversity of neuroinflammatory markers should be evaluated in clinical and biomarker studies in, and beyond, PSP to understand its relevance for patient stratification in disease modifying therapy trials.Competing Interest StatementSLF received funding from the National Health and Medical Research Council of Australia Ideas grant (#214090508). SHF has received clinic support from the Edmond J Safra Foundation for Parkinson Research; Parkinson Foundation and UHN Foundation. Research Funding from Michael J Fox Foundation for Parkinson Research, NIH (Dystonia Coalition); Parkinson Canada; Weston Foundation. Honoraria from the International Parkinson and Movement Disorder Society. Site PI for Clinical Trials for Alexion, Biotie, Consultancy/Speaker fees from Abbvie, Lundbeck, Sunovion; Royalties from Oxford University Press. MCT receives funding from NIH, Weston Brain Foundation, Tanenbaum Institute for Research in Science of Sport, Canadian Institutes of Health Research the Michael J. Fox Foundation and in-kind funding from Roche; she has served as an advisor to Eisai, Lilly and Novo Nordisk; she conducts clinical trials for Biogen, Anavex, Janssen, Novo Nordisk, Passage Bio, Merck, Green Valley, UCB. AEL has served as an advisor for AbbVie, Amylyx, Aprinoia, Biogen, BioAdvance, Biohaven, BioVie, BlueRock, BMS, Denali, Janssen, Lilly, Pharma 2B, Sun Pharma, and UCB; received honoraria from Sun Pharma, and AbbVie; received grants from Brain Canada, Canadian Institutes of Health Research, Edmond J Safra Philanthropic Foundation, Michael J. Fox Foundation, Parkinson Foundation, and Parkinson Canada; received publishing royalties from Elsevier, Saunders, Wiley-Blackwell, Johns Hopkins Press, and Cambridge University Press. AEL has a shared pending patent for Diagnostic assays for movement disorders (18/537,455). GGK reports personal fees from Parexel and Mitsubishi-Tanabe; funding from Rossy Family Foundation, from Edmond Safra Foundation, grants from Krembil Foundation, MSA Coalition, MJ Fox Foundation, Parkinson Canada, NIH, Canada Foundation for Innovation, and Ontario Research Fund outside the submitted work; in addition, GGK has a shared patent for 5G4 Synuclein antibody and a pending patent for Diagnostic assays for movement disorders (18/537,455), and received royalties from Wiley, Cambridge, Taylor and Francis, and Elsevier publishers. AK, HT, SZ, HC, JL, and JW have nothing to disclose.Funding StatementRossy Family foundation. the National Institute on Aging of the National Institutes of Health under Award Number R01AG080001.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Autopsy tissue from human brains was collected with informed consent from patients or their relatives and approval by the University Health Network Research Ethics Board (Nr. 20-5258).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData will be shared upon reasonable request from any qualified investigator.